Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB. Kanai M, et al. Among authors: imaizumi a. Cancer Chemother Pharmacol. 2011 Jul;68(1):157-64. doi: 10.1007/s00280-010-1470-2. Epub 2010 Sep 22. Cancer Chemother Pharmacol. 2011. PMID: 20859741 Free article. Clinical Trial.
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers.
Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H, Chiba T. Kanai M, et al. Among authors: imaizumi a. Cancer Chemother Pharmacol. 2012 Jan;69(1):65-70. doi: 10.1007/s00280-011-1673-1. Epub 2011 May 21. Cancer Chemother Pharmacol. 2012. PMID: 21603867 Free article. Clinical Trial.
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, Murakami Y, Imaizumi A, Chiba T, Nishihira J, Shibata H. Kanai M, et al. Among authors: imaizumi a. Cancer Chemother Pharmacol. 2013 Jun;71(6):1521-30. doi: 10.1007/s00280-013-2151-8. Epub 2013 Mar 30. Cancer Chemother Pharmacol. 2013. PMID: 23543271 Free article. Clinical Trial.
Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin.
Abe T, Horisawa Y, Kikuchi O, Ozawa-Umeta H, Kishimoto A, Katsuura Y, Imaizumi A, Hashimoto T, Shirakawa K, Takaori-Kondo A, Yusa K, Asakura T, Kakeya H, Kanai M. Abe T, et al. Among authors: imaizumi a. Eur J Pharmacol. 2022 Nov 15;935:175321. doi: 10.1016/j.ejphar.2022.175321. Epub 2022 Oct 10. Eur J Pharmacol. 2022. PMID: 36228744 Free article.
Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study.
Nakagawa Y, Mukai S, Yamada S, Matsuoka M, Tarumi E, Hashimoto T, Tamura C, Imaizumi A, Nishihira J, Nakamura T. Nakagawa Y, et al. Among authors: imaizumi a. J Orthop Sci. 2014 Nov;19(6):933-9. doi: 10.1007/s00776-014-0633-0. Epub 2014 Oct 13. J Orthop Sci. 2014. PMID: 25308211 Free PMC article. Clinical Trial.
Innovative preparation of curcumin for improved oral bioavailability.
Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Sasaki H, et al. Among authors: imaizumi a. Biol Pharm Bull. 2011;34(5):660-5. doi: 10.1248/bpb.34.660. Biol Pharm Bull. 2011. PMID: 21532153 Free article. Clinical Trial.
185 results